By showing that patients who presented initial PD on ICI associated to a tumor deceleration (TGKR < 1) had higher ORR that those with tumor acceleration (TGKR > 1), we think that some of the responses in our study were due/enhanced by circulating anti-PD1/PDL1 antibodies causing delayed onset of response. This evidence concerns the gene CD274 and neoplasm.